Oncology Learning Network’s Post

Protein glycosylation plays a crucial role in many biological processes, including tumor progression. As researchers uncover more cancer-related glycosylation patterns, these findings could lead to new methods for early cancer detection, improved prognosis, and therapy development. In this webinar, Drs. Karen Abbott and Susan Bellis explore tools and technologies for discovering and detecting glycan biomarkers. They also explain the role of glycosylation in tumor progression and discuss possible therapeutic options. Watch it here: https://wi.st/3MV2b5Z #Oncology #BiomarkerDiscovery #Glycosylation

The potential of active polymetallic atomic clusters for cutting-edge cancer therapy. By synthesizing bimetallic PtPd atomic clusters (BAC) and leveraging their catalytic prowess, we aim to revolutionize antineoplastic treatment. These clusters, engineered through a meticulous process of stripping Pt and Pd nanoparticles on nitrogen-doped carbon followed by surface PEGylation, exhibit remarkable abilities. Once taken up by tumor cells, BAC acts as a catalyst, breaking down endogenous H2O2 into O2, thus mitigating hypoxia and boosting •O2 − production. Moreover, BAC showcases peroxidase-like activity, yielding •OH from H2O2. This cascade of reactions results in potent oxidative damage, inducing apoptosis. Additionally, BAC's intrinsic GSH peroxidase-like activity indirectly modulates lipid peroxides, fostering ferroptosis and immunogenic cell death, curtailing metastasis. These findings pave the way for more refined designs of polymetallic atomic clusters in disease therapy. Join us in pushing the boundaries of cancer treatment! #CancerResearch #Innovation #Therapeutics #dcrclabs Please find the link of the article https://lnkd.in/g67XBH9g

Common complications associated with arterial punctures include which of the following: I. Fistula formation II. Hematoma formation III. Spasm of the vessel A. I only B. III only C. I and II only D. II and III only

Check out our new research article “Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity”. Abstract as follows: Estrogen receptor α (ERα) is a prime target for the treatment of ER-positive (ER+) breast cancer. Despite the development of several effective therapies targeting ERα signaling, clinical resistance remains a major challenge. In this study, we report the discovery of a new class of potent and orally bioavailable ERα degraders using the PROTAC technology, with ERD-3111 being the most promising compound. ERD-3111 exhibits potent in vitro degradation activity against ERα and demonstrates high oral bioavailability in mice, rats, and dogs. Oral administration of ERD-3111 effectively reduces the levels of wild-type and mutated ERα proteins in tumor tissues. ERD-3111 achieves tumor regression or complete tumor growth inhibition in the parental MCF-7 xenograft model with wild-type ER and two clinically relevant ESR1 mutated models in mice. ERD-3111 is a promising ERα degrader for further extensive evaluations for the treatment of ER+ breast cancer.

Online now: A cyclic peptide-grafted Fc with hepatocyte growth factor functionality ameliorates hepatic fibrosis in a non-alcoholic steatohepatitis mouse model http://dlvr.it/T9cmtS

Earlier this year at SOT Agilent Technologies presented a poster titled 'Evaluating Mitochondrial Dysfunction and Hepatotoxicity in HUREL Micro Liver Co-cultures via Mito Tox Index and Cell Index.' View the poster and their findings here --> https://hubs.ly/Q02SbqPz0 #Visikol #HUREL #MitochondrialDysfunction #Hepatoxicity

ß2 microglobulin (B2m) is a protein of low molecular weight (11800 Da) which forms the light chain of antigens of Class I Major Histocompatibility Complex (MHC) and is therefore found in the membrane of most nucleated cells, and in particularly high concentrations on the surface of lymphocytes. In free form, B2m is found in both serum and urine of normal individuals. Visit our website to know everything about our Beta-2 Micro assays. https://lnkd.in/dU5DwNp8 #Beta2Microglobulin #B2m #Microglobulin #IFCC #ClinicalChemistry #Turbidimetry

Figure 3 The impact of lipoprotein(a) on atherosclerotic process and atherothrombosis. Lp(a) increases atherosclerotic plaque vulnerability, vascular smooth muscle cell proliferation and adhesion of molecules, chemotactic factors and plasma cytokines. Moreover, Lp(a) enhances platelet activation and aggregation and inhibits fibrinolysis by inhibiting plasminogen activation. Lp(a) inhibits TFPI and enhances expression of TF. Moreover, Lp(a) induces increased expression of PAI-1.

Announced a phase 3 CT evaluating oral APX3330 for the treatment of moderate to severe NPDR, with the potential to slow or prevent progression of DR with a favorable safety profile. It is an oral small molecule, that inhibits the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1) and modulates the downstream pathways regulated by Ref-1 – which involve angiogenesis (VEGF), oxidative stress (Nrf2) and inflammation (NFkB) – to restore homeostatic levels.

#ESMOGI24: Promising data from the phase III NETTER-2 study show that peptide receptor radionuclide therapy significantly improves outcomes for patients with grade 2 high-grade 3 low gastroenteropancreatic neuroendocrine tumours (GEP-NETs), regardless of tumour grade or primary origin. According to Rocio Garcia-Carbonero, commenting on these results for the #ESMODailyReporter, this study supports the use of 177Lu-DOTATATE as a frontline treatment for somatostatin receptor-positive grade 3 low GEP-NETs, and possibly selected patients with grade 2 high GEP-NETs. 📌https://ow.ly/aJ9m50Sq7NU